Department of Microbiology
Xueen Liu
Liu Xueen, Associate Professor
Department of Microbiology, Peking University Health Science Center
CONTACT INFORMATION
E-mail: xueenliu@bjmu.edu.cn
EDUCATION AND WORKING EXPERIENCE
2004.8-present. Department of Microbiology, Peking University Health Science Center
Associate professor
2005.8-2007.3 Department of Molecular Biomedical Research, University of Ghent
Postdoctoral researcher
2001.9-2004.7 Department of Microbiology, Peking University Health Science Center
Assistant professor
1992.8-2001.8 School of Public Heath, Beijing Medical University
Assistant professor
1996.8-1999.7 Beijing Medical University
Master degree of Medicine
1986.8-1992.7 Beijing Medical University
Bachelor degree of Medicine
PROJECTS
1. The National Science & Technology Major Project of China Thirteenth Five-year Plan for Infectious Diseases（Grant no. 2017ZX10732401）
2. The National Science & Technology Major Project of China Twelfth Five-year Plan for Infectious Diseases （Grant no. 2013ZX10002004）
3. The National Science & Technology Major Project of China Eleventh Five-year Plan for Infectious Diseases （Grant no. 2009ZX10004-314）
4. Prediction of liver disease with serum protein glycomics: non-invasive diagnosis of liver fibrosis, cirrhosis and hepatocellular carcinoma，The joint project between China and Belgium，（2005-2007）
5. The project of Peking University - SysDiagno Biotech Joint Laboratory of Glycomics. (2021-2024)
6. Comparative immunogenicity of hepatitis B vaccine with different dosages and schedules among healthy young adults. (2014-2018) (The cooperation project with Shenzhen Kangtai Biological Products Co., Ltd)
7. A follow-up study on the efficiency of live attenuated and inactivated HAV vaccine and the persistent of Anti-HAV IgG. (2008-2013) (The cooperation project with Sinovac Biotech Co., Ltd)
PUBLICATIONS （Corresponding/first author）
1. Dong HJ, Li XH, Gu QX, Ma CF, Yuan MX, Wang ZZ, Su JR, Xu L, Chen CY, Ebule Q, Zhuang H, Liu XE. N-glycan as new potential biomarker for predicting treatment response in patients with type 2 diabetes mellitus, Biomarkers in Medicine, 2024，18（24）：1113-1122.
2. Duan M, Xiao H, Shi M, Xie Y, Zhao P, Li S, Chi X,Liu XE, Zhuang H. Significant liver histological change is common in HBeAg-positive chronic hepatitis B with normal ALT BMC Infect Dis. 2024, 23;24(1):723.
3. Wang L, Liu YQ, Gu QX, Zhang C, Xu L, Wang L, Chen CY, Liu XE, Zhao H, Zhuang H. Serum N-glycan markers for diagnosing significant liver fibrosis and cirrhosis in chronic hepatitis B patients with normal ALT levels. Engineering, 2023, 26:151-158.
4. Duan MH, Chi XL,Xiao HM, Liu XE, Zhuang H. High‑normal alanine aminotransferase is an indicator for liver histopathology in HBeAg‑negative chronic hepatitis B Hepatol Int 2021,15(2):318-327.
5. Cao X, Shang QH, Chi XL, Zhang W, Xiao HM, Sun MM, Chen G, An Y, Lü CL, Wang L, Nan YM, Chen CY, Tan ZN, Liu XE, Zhuang H Serum N-glycan markers for diagnosing liver fibrosis induced by hepatitis B virus World journal of gastroenterology 2020, 26(10): 1067-1079.
6. Gao YH, Yang J, Sun F, Zhan SY, Fang ZL, Liu XE, Zhuang H. Prevalence of anti-HCV antibody among the general population in Mainland China between 1991 and 2015: a systematic review and meta-analysis. Open Forum infectious diseases 2019; 6(3):ofz040(1-7).
7. Wang L, Lu W, Gao YH, Yan HJ, Pei F, Liu XE, Zhuang H. Anluohuaxianwan alleviates CCL4-induced hepatic fibrosis in rats through upregulation of PPARγ and downregulation of NF-κB/IκBα signaling pathway. World Journals of Traditional Chinese Medicine 2019; 5(2):95-103.
8. Wang L, Cao X, Wang ZZ, Gao YH, Deng J, Liu XE, Zhuang H . Correlation of HBcrAg with intrahepatic hepatitis B virus total DNA and covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients. Journal of clinical microbiology 2018, 57:e01303-18.
9. Wang ZZ, Gao YH, Wang P, Wei L, Xie CP, Yang ZX, Lan J, Fang ZL, Zeng Y, Yan L, Liu XE, Zhuang H. Comparison of immunogenicity between hepatitis B vaccine with different dosages and schedules among healthy young adults in China: A 2-year follow-up study Human vaccines and immunotherapeutics 2018;14(6):1475-1482.
10. Gao YH, Li YT, Meng QH, Zhang ZQ, Zhao P, Shang QH, Li Y, Su MZ, Li T, Liu XE, Zhuang H. Serum hepatitis B virus DNA, RNA, and HBsAg: which correlated better with intrahepatic covalently closed circular DNA before and after nucleos(t)ide analogue treatment? Journal of clinical microbiology 2017; 55(10): 2972-2982.
11. Wang ZZ, Gao YH, Lu W, Jin CD, Zeng Y, Yan L, Ding F, Li T, Liu XE, Zhuang H. Long-term persistence in protection and response to a hepatitis B vaccine booster among adolescents immunized in infancy in the western region of China Human vaccines and immunotherapeutics 2017; 13(4): 909-915.
12. Gao YH, Meng QH, Zhang ZQ, Zhao P, Shang QH, Yuan Q, Li Y, Deng J, Li T, Liu XE, Zhuang H. On-treatment quantitative HBeAg predicted response to nucleos(t)ide analogues in chronic hepatitis B World journal of hepatology 2016; 8(34): 1511-1520.
13. Wang ZZ, Li MQ, Wang P, Yang ZX, Wei L, Zeng Y, Li YP, Yan L, Liu XE, Zhuang H. Comparative immunogenicity of hepatitis B vaccine with different dosages and schedules in healthy adults in China. Vaccine. 2016; 34:1034-1039.
14. Li Y, Huang YS, Wang ZZ, Sun F, Zhan SY, Liu XE, Zhuang H. Systematic Review with Meta-analysis: The Diagnostic Accuracy of Transient Elastography for the Staging of Liver Fibrosis in Patients with Chronic Hepatitis B. Alimentary Pharmacology & Therapeutics. 2016; 43:458-469.
15. Liu XE, Chen HY, Liao Z, Zhou YS, Wen HR, Peng SH, Liu Y, Li R, Li J, Zhuang H. Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccines among young adults: a three-year follow-up study, Journal of Infectious Diseases Journal of Infectious Diseases. 2015, 212(8): 1232-1236.
16. Qiu N, Li R, Yu JG,Yang W, Zhang W, An Y, Li T, Liu XE, Zhuang H. Comparison of Abbott and Da-an real-time PCR assays for quantitating serum HBV DNA. World journal of gastroenterology 2014; 20（33）11762-11769.
17. Liu XE, Wushouer F, Gou AL, Kuerban M, Li XL, Sun YB, Zhang JM, Liu Y, Li J, Zhuang H. Comparison of immunogenicity between inactivated and live attenuated hepatitis A vaccines: a single-blind, randomized, parallel-group clinical trial among children in Xinjiang Uighur Autonomous Region, China. Human Vaccines and Immunotherapeutics 2013，9（7）：1-6.
18. Wang MR, Qiu N, Lu SC, Xiu DR, Yu JG, Wang XT, Lu FM, Li T, Liu XE,Zhuang H. Serum hepatitis B surface antigen is correlated with intrahepatic total HBV DNA and cccDNA in treatment-Naïve patients with chronic hepatitis B but not in patients with HBV related hepatocellular carcinoma. Journal of Medical Virology. 2013, 85(2): 219-227.
19. Liu XE, Dewaele.S, Vanhooren V, Fan YD, Wang L, Van Huysse J, Zhuang H, Contreras R, Libert C, Chen CY. Alteration of N-glycome in diethylnitrosamine-induced hepatocellular carcinoma mice :a non-invasive monitoring tool for liver cancer. Liver International. 2010,30(8):1221-8.
20. Liu XE, Desmyter L, Gao CF, Laroy W, Dewaele S, Vanhooren V, Wang L, Zhuang H, Callewaert N, Libert C, Contreras R, Chen C. N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology. 2007, 46(5):1426-1435.